Aventis Insulin Analog Lantus® Launched in the USA
A diabetes medication that in less than a year has become one of the leading components of diabetes treatment in Germany, was introduced today in the United States. Lantus® (insulin glargine), the first and only insulin analog that provides 24-hour glucose lowering activity while being administered just once per day, is now available by prescription in US pharmacies.
Lantus is unique in that it has no pronounced peak, and is indicated for once-daily administration at bedtime in the treatment of adult and pediatric patients (6 years of age and older) with type 1 diabetes, or adult patients with type 2 diabetes who require long-acting insulin for the control of hyperglycemia. Lantus was first launched in Germany in June 2000, and has already captured 28 percent of the basal insulin market there.
“This product could change, for the better, the way diabetes is treated,â€
Other news from the department
